On Saturday, April 2nd, we at Tact.ai attended the 71st Annual American College of Cardiology Scientific Sessions (ACC.22) in Washington, D.C. We were absolutely thrilled to be a part of discussions about the most recent cardiovascular research and to promote meaningful customer engagement with our Human-friendly and HCP-centric software.
This year's conference, which included both in-person and virtual attendance options, was one of the largest in the cardiovascular space, attracting physicians, scientists, and other ACC members from around the world. Thousands of cardiovascular professionals from the globe came together to debate and discuss practice-changing science and innovations.
There were around 300 sessions that were live on-site, while 80 were live for the remote attendees, creating a truly hybrid experience. Themes for the sessions ranged from addressing the impact of social determinants of health on cardiovascular outcomes to understanding the most recent innovations in digital health. Personally, finding out that having two to three cups of coffee a day was associated with the greatest health benefits, translating to a 10-15% lower risk of developing heart disease made my day!
It was a pleasure supporting our customers at the ACC and getting the opportunity to connect with so many brilliant experts from across the globe in cardiology. A live event of this magnitude seemed to be sorely missed after a very long couple of years. The sheer curiosity for science and innovation seemed to be at an all-time high and it was an honor to discuss how Tact.ai has quickly emerged these past couple of years to help all types of healthcare and life science organizations connect in a HIPAA / GDPR compliant platform.
We were excited about introducing our partnership with Esperion- a leader in LDL-C reduction and cardiovascular health, which discovers, develops, and commercializes medicines that help patients reduce their cardiovascular risk.
We were delighted to observe the shifts and the renewed enthusiasm in-person in the cardiology space and to also share the best practices around creating an omnichannel, holistic, and outcome-centric customer engagement experience for HCPs in the post-pandemic world.
With the increase in demand for real-time interactions from HCPs and over 65% of physicians wanting pharma reps to be able to discuss real-world data with them, we at Tact help pharmaceutical companies with the next generation of HCP engagement.
In the evolving life sciences landscape and increased digital access, the Tact platform supports hybrid HCP engagement by combining and aligning the face-to-face, phone, email, video, chat, and self-service modes of engagement. The Tact customer engagement platform helps life sciences companies deliver personalization at scale while diversifying their technology stack with best-in-class tools.
We at Tact thrive to help pharmaceutical companies engage HCPs and Key Opinion Leaders to nurture meaningful engagement through our human-friendly software.
We were honored to be a part of The American College of Cardiology Scientific Sessions 2022 and get glimpses of a world where innovation and knowledge optimize cardiovascular care and outcomes.
This week on May 17th and 18th, our team at Tact.ai attended the Next Pharma Summit 2022.Our team was delighted to be a part of the discussions about the future of customer engage
Tact’s immersive and connected customer experience helps customer-facing teams to create a true, no-friction, omnichannel on-demand experience for HCPs.
Gartner has included Tact.ai, the customer engagement company for life sciences, in its Hype Cycle for Life Sciences Commercial Operations.
Tact customer engagement platform drives the last mile of the Next Best Action engine or other Customer Insights Programs enabling field teams with greater actionability
Pharma and life sciences companies who want to win the attention of healthcare providers in 2022 will need to do a better job of connecting with them on their own terms